• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

    56.03 +2.02 (+3.75%)
    Streaming Delayed Price Updated: 1:54 PM EDT, Jul 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,089,230
    Open 53.71
    Bid (Size) 56.00 (100)
    Ask (Size) 56.07 (200)
    Prev. Close 54.01
    Today's Range 53.35 - 57.48
    52wk Range 40.03 - 86.74
    Shares Outstanding 141,797,854
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Cathie Wood Just Bet Big on This Biotech Stock ↗
    Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing? 
    Via The Motley Fool
    Topics ETFs

    Performance

    YTD
    -29.7%
    -29.7%
    1 Month
    -26.2%
    -26.2%
    3 Month
    -25.1%
    -25.1%
    6 Month
    -29.5%
    -29.5%
    1 Year
    +33.6%
    +33.6%

    More News

    Read More
    News headline image
    Ionis to hold second quarter 2026 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
    Via MarketBeat
    News headline image
    IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
    Via InvestorPlace
    News headline image
    Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗
    Via MarketBeat
    News headline image
    Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗
    Via MarketBeat
    News headline image
    Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to host 2026 virtual Annual Meeting of Stockholders
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
    Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
    What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
    The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 56.03
    When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 07/23/26 01:54 PM ET
    What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 7.95B
    How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Ionis Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.